Abstract
The present study aims to assess the effect of age on doxorubicin kinetic disposition and metabolism in breast cancer patients. Forty (40) breast cancer patients in the first cycle of treatment with the doxorubicin-cyclophosphamide regimen will be divided into two groups: control group including younger patients (< 60 years) and study group including elderly patients (> 60 years). Patient…